NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

NMTR

NMTR US Stock
$1.05
Open: $1.06 High: $1.18 Low: $1.02 Close: $1.04
Range: 2021-04-19 - 2021-04-20
Volume: 6,705,255
Market: Extended-hours
Powered by Finage Stock APIDelayed data
NMTR
  • CEO:
  • Employees:
  • Sector:
  • Industry:
NMTR News
Latest news about the NMTR
  • 9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome

    RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

    View More →
  • 9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study

    RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will collaborate with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters' Phase 3 study, CeDLara, for their drug candidate larazotide in celiac disease.

    View More →
  • 9 Meters Biopharma Announces Closing of Offering of Common Stock

    RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previously announced underwritten public offering of 34,500,000 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $1.

    View More →
  • 9 Meters Biopharma Prices Public Offering of Common Stock

    RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.

    View More →
  • 9 Meters Biopharma Announces Proposed Public Offering of Common Stock

    RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock.

    View More →
  • Did 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Insiders Buy Up More Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

    View More →
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020

    jsp for registration detailsRALEIGH, NC / ACCESSWIRE / March 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today provided an overview of its recent achievements and 2021 outlook and reported its financial results for the fourth quarter and full year ended December 31, 2020.

    View More →
  • 9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

    Tuesday, March 23rd @ 11am Eastern TimeRALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time.The webinar will feature presentations by KOLs Carol Rees Parrish, M.

    View More →
  • 9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences

    \- Oppenheimer 31st Annual Healthcare Conference - March 16th \- 18th\- Maxim Group 2021 Emerging Growth Virtual Conference -March 17th \- 18thRALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that management will participate in the following conferences in the month of March and invites investors to participate by webcast or one-on-one meetings.

    View More →
  • 9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop

    RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patrick Griffin, M.

    View More →
  • 9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors

    RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.

    View More →
  • 9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference

    RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Investor Conference.

    View More →
  • 9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?

    9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

    View More →
  • 9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series

    RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the "CEO Strategic Vision" Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, February 10, 2021.

    View More →
  • 9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome

    SAVE THE DATE: Webinar Scheduled for March 23, 2021 @ 11 AM ET RALEIGH, NC / ACCESSWIRE / February 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a research and development day webinar on its clinical development program to treat short bowel syndrome (SBS) on Tuesday, March 23, 2021 at 11:00 am Eastern Time.

    View More →
  • 2 “Strong Buy” Penny Stocks That Could Deliver Massive Returns

    There’s a strong feeling growing among investors – of relief – that the new year will feature lower volatility than 2020. That along would be enough to boost spirits, but better yet, there is also a perception that the markets are going to drive higher in the new year.Marko Kolanovic, JPMorgan’s well-known quant expert, sees the initial stages of a positive feedback loop, with lower volatility and systematic investment strategies coming together to drive gains, attracting more investors – and, in Kolanovic’s view, pushing the S&P 500 to 4,600 by year’s end. That will be a 25% increase for the index.A general market environment like that is bound to produce plenty of stock winners, and Wall Street’s analysts are busy pointing them out. Among other things, they are tapping penny stocks, equities priced at less than $5 per share. Their rock-bottom starting price makes pennies the logical place to look for huge returns on investment. Although their risk factor is high, even a small gain in absolute numbers will turn into a massive percentage gain in share price.Using TipRanks’ database, we identified two penny stocks the pros believe could see explosive gains in the coming months. Not to mention each one gets a “Strong Buy” consensus rating from the analyst community.9 Meters Biopharma (NMTR)Some biopharma companies take a broad-based approach, while others focus on a niche. 9 Meters is one of the latter, taking aim at unmet needs for gastrointestinal patients. The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat.Drilling down to pipeline details, 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021.Furthermore, this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19.The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients.NMTR’s strong pipeline and $0.89 share price have scored it substantial praise from the pros on Wall Street.One of these NMTR bulls is Truist’s Srikripa Devarakonda. Citing Larazotide as a key component of his bullish thesis, the analyst noted, “We acknowledge investors are likely to see a pivotal trial in a tough-to-crack Celiac disease program as high risk despite encouraging Ph2b data. We model $705M/$353M in peak unadjusted/adjusted sales and see potential upside of 400% - 1650% from positive Ph3 readout.”Devarakonda also sees “significant unmet need in SBS” and continues to believe that “NM-002 has a differentiated profile vs. SOC.” His key takeaways from the recent Phase 1b/2a results include: “1) we believe that the drug showed early activity in SBS patients; all 9 patients showed meaningful reduction in total stool output volume; average TSO reduction was 42% from baseline; 2) responses occur rapidly, with effects on TSO seen within 48 hours of dosing; 3) safety profile looks favorable, we would like to see greater durability.”To this end, Devarakonda rates NMTR shares a Buy along with a $5 price target. This figure conveys his confidence in NMTR’s ability to soar 462% in the coming year. (To watch Devarakonda’s track record, click here)Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given its $4.33 average price target, upside of 386% could be in store for investors. (See NMTR stock analysis on TipRanks)Orchard Therapeutics (ORTX)Orchard Therapeutics takes the broad-based approach to the biopharma industry. The company is engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body.Orchard’s pipeline demonstrates the diversity of disorders amenable to gene therapy – the company has no less than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out.Libmeldy is in commercialization stages as a treatment for MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system. Libmeldy, which is designed to treat children suffering from the infantile for juvenile forms of MLD by replacing the defective ARSA gene, received its approval for medical use in the EU in December 2020.Wedbush analyst David Nierengarten notes the European approval of Libmeldy, and its implication for Orchard’s progress. He writes, “We look forward to the company’s commercial execution in the EU and an eventual 2022 approval in the US. Last month ORTX received IND clearance from the FDA for the program paving the way for discussions with the US regulators to decide a suitable path forward toward a BLA filing.”"Net-net, with possibly two gene therapies approved in the next 12-18 months and a pivotal study beginning in a third (MPS-I), we think ORTX shares are undervalued at these levels," the analyst concluded. In line with his bullish comments, Nierengarten rates ORTX as Outperform (i.e. Buy), and his $15 price target indicates a potential for 241% growth in the year ahead. (To watch Nierengarten’s track record, click here)Do other analysts agree with Nierengarten? They do. Only Buy ratings, 3, in fact, have been issued in the last three months. Therefore, ORTX gets a Strong Buy consensus rating. At $15, the average price target indicates shares could appreciate by 241% in the year ahead. (See ORTX stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • 9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications

    * Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patients * EBRIS will advance larazotide into an Australian Investigational New Drug * Phase 1 study expected to begin in 2021 RALEIGH, NC and SALERNO, ITALY / ACCESSWIRE / December 21, 2020 / 9 Meters Biopharma, Inc.

    View More →
  • 9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock

    RALEIGH, NC / ACCESSWIRE / December 15, 2020 / 9 Meters Biopharma, Inc.

    View More →
  • 9 Meters Biopharma, Inc. Prices Public Offering of Common Stock

    RALEIGH, NC / ACCESSWIRE / December 11, 2020 / 9 Meters Biopharma, Inc.

    View More →
  • 9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD)

    aGvHD among potential indications being considered for next stage of developmentCandidate to move to IND-enabling studies in 2021RALEIGH, NC / ACCESSWIRE / December 9, 2020 / 9 Meters Biopharma, Inc.

    View More →